The efficacy and safety of dipyrone (Novalgin (R)) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multi-center study

Basit Öğe Kaydı
dc.contributor.authorTulunay, F. Cankat
dc.contributor.authorErgün, Hakan
dc.contributor.authorGülmez, Sinem Ezgi
dc.contributor.authorÖzbenli, Taner
dc.contributor.authorÖzmenoğlu, Mehmet
dc.contributor.authorBoz, Cavit
dc.contributor.authorInan, Levent
dc.date.accessioned2020-06-25T17:40:06Z
dc.date.available2020-06-25T17:40:06Z
dc.date.issued2004
dc.departmentKırıkkale Üniversitesi
dc.descriptionGulmez, Sinem Ezgi/0000-0001-8815-9128; ERGUN, HAKAN/0000-0002-7839-966X
dc.description.abstractDipyrone, an effective analgesic drug, is widely used in the management of headache. However, few studies have evaluated its efficacy and safety in migraine. We aimed to assess the efficacy and safety of 1 g dipyrone (Novalgin(R), two 500 mg tablets) on pain and related symptoms in acute migraine attacks with or without aura in a double-blind, cross-over, randomized, placebo-controlled, multi-center study design. Seventy-three migraine with or without aura patients, diagnosed according to the IHS criteria, were randomized to receive dipyrone (for 2 attacks) and placebo (for 1 attack). Pain intensity was measured on a four-point verbal pain scale before and 1, 2, 4 and 24 hours after drug intake. Significant improvement of pain was achieved with dipyrone compared to placebo at all time points measured. Both patient and physician evaluations were significantly in favor of dipyrone. Side effects were few and trivial in both groups. We conclude that dipyrone is an effective, safe and cost-effective option in acute migraine management.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.endpage202en_US
dc.identifier.issn0393-5264
dc.identifier.issue3en_US
dc.identifier.pmid15595715
dc.identifier.startpage197en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12587/3270
dc.identifier.volume19en_US
dc.identifier.wosWOS:000226353400008
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherC I C-Edizioni Internazionali Srlen_US
dc.relation.ispartofFunctional Neurology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectacute treatmenten_US
dc.subjectdipyroneen_US
dc.subjectmigraineen_US
dc.subjectplaceboen_US
dc.titleThe efficacy and safety of dipyrone (Novalgin (R)) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multi-center studyen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
The efficacy and safety of dipyrone (Novalgin (R)) tablets in the treatment of acute migraine attacks a double-blind, cross-over, randomized, placebo-controlled, multi-center study.pdf
Boyut:
56.28 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu